Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genzyme, Icahn Call Off Proxy Fight
by Marc S. Reisch
June 14, 2010
| A version of this story appeared in
Volume 88, Issue 24
Genzyme and activist investor Carl Icahn have agreed to settle their proxy contest. Under the agreement, Icahn will withdraw his own name and those of three other nominees for the board and vote his Genzyme shares in favor of the company’s nominees. In return, Genzyme agreed to appoint two Icahn nominees immediately following the firm’s June 16 annual meeting. In May, Genzyme launched a $2 billion stock buyback program and said it would sell three businesses (C&EN, May 17, page 17).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter